Pub Date : 2022-09-30DOI: 10.31487/j.jicoa.2022.03.05
Steven Imburgio, Anmol Johal, N. Udongwo, A. Mararenko, Anas Alrefaee, Joseph N Heaton
BRASH syndrome is a newly coined diagnosis consisting of the clinical pentad of bradycardia, renal failure, atrioventricular (AV) nodal blockade, shock, and hyperkalemia. It is a rare syndrome with just under 50 reported cases. This case report and literature review present a case of BRASH syndrome, refractory to pharmaceutical measures, and subsequent literature review to assess treatment decisions and overall outcomes. The consensus from the literature supports the use of advanced interventions in most cases, including transcutaneous or transvenous pacing, hemodialysis, and adrenergic support. The early recognition and initiation of treatment in this patient demographic are paramount to reducing possible multi-system organ damage and mortality. This case report and literature review aim to improve patient outcomes and help further elucidate a protocol for treating BRASH syndrome.
{"title":"BRASH Syndrome: A Case Report and Literature Review","authors":"Steven Imburgio, Anmol Johal, N. Udongwo, A. Mararenko, Anas Alrefaee, Joseph N Heaton","doi":"10.31487/j.jicoa.2022.03.05","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.03.05","url":null,"abstract":"BRASH syndrome is a newly coined diagnosis consisting of the clinical pentad of bradycardia, renal failure, atrioventricular (AV) nodal blockade, shock, and hyperkalemia. It is a rare syndrome with just under 50 reported cases. This case report and literature review present a case of BRASH syndrome, refractory to pharmaceutical measures, and subsequent literature review to assess treatment decisions and overall outcomes. The consensus from the literature supports the use of advanced interventions in most cases, including transcutaneous or transvenous pacing, hemodialysis, and adrenergic support. The early recognition and initiation of treatment in this patient demographic are paramount to reducing possible multi-system organ damage and mortality. This case report and literature review aim to improve patient outcomes and help further elucidate a protocol for treating BRASH syndrome.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49457787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-23DOI: 10.31487/j.jicoa.2022.03.04
K. Ferrick, Alexander Conant, Jay J Chudow, Syona S Shetty, Rahul Grover, John D Fisher, A. Krumerman
Fast and accurate identification of cardiac devices can facilitate device programming and interrogation in various medical settings. We have previously demonstrated the accuracy of the PacemakerID machine learning algorithm for mobile phone cardiac device identification. However, the questions of the reproducibility of this algorithm and whether a single trial sufficiently maximizes accuracy have yet to be answered. Here, we examine 502 chest x-rays performed at a single institution on patients with implantable cardioverter-defibrillators and permanent pacemakers. The PacemakerID mobile phone application was used for five sequential trials on each image and the accuracy of one, three, and five trials were compared. A single trial resulted in a 79% accuracy and 82% positive predictive value with no significant difference (p=0.69) as compared to five trials at identifying device manufacturers. Across all devices, the results of a single trial were not significantly different from those of five trials. Our data demonstrate that a single trial is sufficient to maximize diagnostic accuracy with the PacemakerID mobile phone application, facilitating rapid identification for prompt programming and interrogation of cardiac devices.
{"title":"Accuracy of a Single Versus Multiple Trials of Novel Pacemaker ID Algorithm Mobile Phone App for Identification of Cardiac Devices","authors":"K. Ferrick, Alexander Conant, Jay J Chudow, Syona S Shetty, Rahul Grover, John D Fisher, A. Krumerman","doi":"10.31487/j.jicoa.2022.03.04","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.03.04","url":null,"abstract":"Fast and accurate identification of cardiac devices can facilitate device programming and interrogation in various medical settings. We have previously demonstrated the accuracy of the PacemakerID machine learning algorithm for mobile phone cardiac device identification. However, the questions of the reproducibility of this algorithm and whether a single trial sufficiently maximizes accuracy have yet to be answered. Here, we examine 502 chest x-rays performed at a single institution on patients with implantable cardioverter-defibrillators and permanent pacemakers. The PacemakerID mobile phone application was used for five sequential trials on each image and the accuracy of one, three, and five trials were compared. A single trial resulted in a 79% accuracy and 82% positive predictive value with no significant difference (p=0.69) as compared to five trials at identifying device manufacturers. Across all devices, the results of a single trial were not significantly different from those of five trials. Our data demonstrate that a single trial is sufficient to maximize diagnostic accuracy with the PacemakerID mobile phone application, facilitating rapid identification for prompt programming and interrogation of cardiac devices.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45689246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Central venous catheterization (CVC) is a routine technique done in critical care and emergency departments for monitoring patients and giving certain parenteral medications in special conditions. Most common complications associated with CVCs are infection, hematoma, hemothorax, pneumothorax and superior or inferior vena cava trauma while rare complications include cardiac arrhythmias, air embolism and loss of the guide wire [1].
{"title":"A Catastrophe Caused by Central Venous Catheter Insertion – A Case Report","authors":"","doi":"10.33140/coa.01.01.04","DOIUrl":"https://doi.org/10.33140/coa.01.01.04","url":null,"abstract":"Central venous catheterization (CVC) is a routine technique done in critical care and emergency departments for monitoring patients and giving certain parenteral medications in special conditions. Most common complications associated with CVCs are infection, hematoma, hemothorax, pneumothorax and superior or inferior vena cava trauma while rare complications include cardiac arrhythmias, air embolism and loss of the guide wire [1].","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76128880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-10DOI: 10.33140/coa/01/01/00005
Cardiovascular disease (CVD) is the leading cause of death today and a burden on a country’s economic growth. Management of this disease continues to depend on dietary control and statins. However, the disease burden refuses to decline. It is probably because treatment regime addresses the effect and not the cause. Augmented LDL level has been traditionally perceived as the major risk factor contributing to the development of atherosclerosis, the main cause of several coronary ailments. Recent research also suggests that pre-existing chronic inflammation leads to oxidation of LDL and thus makes it pathogenic. This inflammatory repertoire, apart from leukocytes, also includes the anucleated cell fragments called platelets. Platelets conventionally associated with clotting phenomenon, also express array of inflammatory mediators creating a crucial link between immune response and thrombotic complications. In this review we will examine the role of inflammation as a primary causative agent of atherosclerotic as well as non-atherosclerotic cardiovascular diseases.
{"title":"Insights into Cardiovascular Diseases: The Vicious Platelet-Immune System Loop","authors":"","doi":"10.33140/coa/01/01/00005","DOIUrl":"https://doi.org/10.33140/coa/01/01/00005","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of death today and a burden on a country’s economic growth. Management of this disease continues to depend on dietary control and statins. However, the disease burden refuses to decline. It is probably because treatment regime addresses the effect and not the cause. Augmented LDL level has been traditionally perceived as the major risk factor contributing to the development of atherosclerosis, the main cause of several coronary ailments. Recent research also suggests that pre-existing chronic inflammation leads to oxidation of LDL and thus makes it pathogenic. This inflammatory repertoire, apart from leukocytes, also includes the anucleated cell fragments called platelets. Platelets conventionally associated with clotting phenomenon, also express array of inflammatory mediators creating a crucial link between immune response and thrombotic complications. In this review we will examine the role of inflammation as a primary causative agent of atherosclerotic as well as non-atherosclerotic cardiovascular diseases.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90265757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Takayasu Arteritis (TAK) is a subgroup of large vessel vasculitis involving major branches of aorta. Corticosteroids are the mainstay of treatment. However, several other steroid-sparing agents are used to control vessel wall inflammation in TAK. Some biologic agents are used as new targeted agents. Several reports denote clinical efficacy of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) blocking agents in management of TAK. While few studies are devoted to report B cell depletion in inflammation in TAK, we report a 34-year-old woman with established diagnosis of TAK treated with rituximab with good clinical and laboratory control.
{"title":"Rituximab in Takayasu Arteritis, a Case Report","authors":"","doi":"10.33140/coa.01.01.01","DOIUrl":"https://doi.org/10.33140/coa.01.01.01","url":null,"abstract":"Takayasu Arteritis (TAK) is a subgroup of large vessel vasculitis involving major branches of aorta. Corticosteroids are the mainstay of treatment. However, several other steroid-sparing agents are used to control vessel wall inflammation in TAK. Some biologic agents are used as new targeted agents. Several reports denote clinical efficacy of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) blocking agents in management of TAK. While few studies are devoted to report B cell depletion in inflammation in TAK, we report a 34-year-old woman with established diagnosis of TAK treated with rituximab with good clinical and laboratory control.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"183 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74649415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Lotan, Y. Wasserstrum, M. Hallerstrom, Y. Brodov, Y. Adler, G. Segal, Amir, Dagan
A 75 year old female receiving dialysis 3 times weekly due to end-stage renal disease (ESRD), secondary to polycystic kidney disease, presented to the emergency room. She complained of right upper quadrant pain together with pleuritic chest pain. The chest pain worsened on deep inspiration and on lying down flat, but improved on sitting up and bending forwards. An abdominal ultrasound, performed due to a known liver cyst, revealed a solid dense lesion, which was not indicative of a cyst. There was the suspicion that the lesion may have been infectious or hemorrhagic in nature. As a result the patient was admitted to the surgical department for further evaluation. Due to her failure to respond to antibiotic treatment a PET-CT with F-18-FDG was ordered. The studies revealed increased mediastinal absorption between her large vessels and pericardium as well as a small pericardial effusion. Her serum CRP peak was 236.83 mg/l, the troponin was negative and her blood urea was 42 mg/dl (15-45 mg/dl). The ECG did not show any typical changes of pericarditis.
{"title":"Management of Resistant Pericarditis in an End Stage Renal Disease Patient - Case Presentation","authors":"D. Lotan, Y. Wasserstrum, M. Hallerstrom, Y. Brodov, Y. Adler, G. Segal, Amir, Dagan","doi":"10.33140/coa.01.01.03","DOIUrl":"https://doi.org/10.33140/coa.01.01.03","url":null,"abstract":"A 75 year old female receiving dialysis 3 times weekly due to end-stage renal disease (ESRD), secondary to polycystic kidney disease, presented to the emergency room. She complained of right upper quadrant pain together with pleuritic chest pain. The chest pain worsened on deep inspiration and on lying down flat, but improved on sitting up and bending forwards. An abdominal ultrasound, performed due to a known liver cyst, revealed a solid dense lesion, which was not indicative of a cyst. There was the suspicion that the lesion may have been infectious or hemorrhagic in nature. As a result the patient was admitted to the surgical department for further evaluation. Due to her failure to respond to antibiotic treatment a PET-CT with F-18-FDG was ordered. The studies revealed increased mediastinal absorption between her large vessels and pericardium as well as a small pericardial effusion. Her serum CRP peak was 236.83 mg/l, the troponin was negative and her blood urea was 42 mg/dl (15-45 mg/dl). The ECG did not show any typical changes of pericarditis.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"207 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80490089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-05DOI: 10.31487/j.jicoa.2022.03.01
K. Adoubi, E. Soya, F. Diby, T. Niamkey, P. Ouattara, Chrisophe Konin
Background: New classification of heart failure according to ejection fraction calls for exploring in black Africans. Objectives: To determine our patient's characteristics and prognosis of the subtypes of heart failure. Methods: We analysed data from consecutive black African patients hospitalised for heart failure at Heart Institute of Abidjan in 2018 and followed up for one year. Results: Were considered 251 heart failure patients (age: 55.5 ± 16.3 years, 63.7% of males) with preserved (HFpEF) (18.7%), mid-range (HFmrEF) (17.6%), and reduced ejection fraction (HFrEF) (63.7%). HFpEF patients were older (p <0.0001) and had more frequently. acute pulmonary oedema. From an echocardiographic point of view, HFpEF patients had, on average, a smaller left ventricle than the other patients (p <0.001), but a larger left atrium (p <0.05). Clinically, these patients were admitted more often with acute pulmonary oedema (p = 0.01) and had more often comorbidities (p=0.00)4. However, survival was better with HFpEF patients than HFrEF patients (log-rank = 4.61; p = 0.032). HFmrEF patients have an intermediate profile. Conclusion: In our context, although they have the same expression, HFrEF and HFPEF appear very different. We need further studies for a better understanding of HFmrEF.
{"title":"Clinical Profiles and One-Year Prognosis of Heart Failure in a Sub-Saharan Country of Africa","authors":"K. Adoubi, E. Soya, F. Diby, T. Niamkey, P. Ouattara, Chrisophe Konin","doi":"10.31487/j.jicoa.2022.03.01","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.03.01","url":null,"abstract":"Background: New classification of heart failure according to ejection fraction calls for exploring in black Africans.\u0000Objectives: To determine our patient's characteristics and prognosis of the subtypes of heart failure.\u0000Methods: We analysed data from consecutive black African patients hospitalised for heart failure at Heart Institute of Abidjan in 2018 and followed up for one year. \u0000Results: Were considered 251 heart failure patients (age: 55.5 ± 16.3 years, 63.7% of males) with preserved (HFpEF) (18.7%), mid-range (HFmrEF) (17.6%), and reduced ejection fraction (HFrEF) (63.7%). HFpEF patients were older (p <0.0001) and had more frequently. acute pulmonary oedema. From an echocardiographic point of view, HFpEF patients had, on average, a smaller left ventricle than the other patients (p <0.001), but a larger left atrium (p <0.05). Clinically, these patients were admitted more often with acute pulmonary oedema (p = 0.01) and had more often comorbidities (p=0.00)4. However, survival was better with HFpEF patients than HFrEF patients (log-rank = 4.61; p = 0.032). HFmrEF patients have an intermediate profile.\u0000Conclusion: In our context, although they have the same expression, HFrEF and HFPEF appear very different. We need further studies for a better understanding of HFmrEF.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49665538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-05DOI: 10.31487/j.jicoa.2022.03.02
C. Siafarikas, S. Liatis, C. Kapelios, M. Skouloudi, M. Bonou, J. Barbetseas
Objectives: Optimal regulation of modifiable risk factors, has been proposed as the standard of care, both for primary and secondary prevention of cardiovascular disease (CVD). The aim of this study was to investigate at what extent individuals who experienced an acute coronary syndrome (ACS) had previously been receiving adequate preventive measures against classical risk factors for CVD. Methods: Data were analysed for all 185 hospitalized patients with a diagnosis of ACS in the Cardiology department of our hospital during an annual period (1/7/2019 until 30/6/2020). The study population was divided into two groups, primary and secondary prevention subgroups, according to the previous medical history of CAD. Results: The mean age of the participants was 65.5 ±12.2 years and most patients were male (81.6%). Fifty-seven patients (30.8%) had a history of diabetes mellitus (DM) and 97 (52.4%) had a history of dyslipidemia. Hypertension was present in 101 (54.6%) patients and coronary artery disease (CAD) in 51 (27.9%). In the secondary prevention group, the LDL-C was on target in only one-third, while one out of 5 patients did not use statins. The use of antiplatelet/anticoagulant agents was 94.5%. Among patients with diabetes, only one out of five patients had been using a GLP-1 receptor agonist or/and an SGLT-2 inhibitor, while the HbA1c was on target in half of them. One-quarter of the patients were active smokers. In the primary prevention group, the use of statins was overall low (25.8%) but more frequent in patients with diabetes and those without diabetes at very high-risk (47.1% and 32.1%, respectively). Overall, the LDL-C was on target in less than one-quarter of patients. The use of antiplatelet/anticoagulant agents was low (20.1%), but higher in those with diabetes (52.9%). In the diabetic group, HbA1c was on target at 61.8%. Active smoking was practiced by more than one-third of the patients. Conclusion: Our data show that in a substantial proportion of patients presenting with ACS, previous CVD prevention, both primary and secondary, fails to meet the current recommendations provided by scientific societies.
{"title":"Patients Presenting with Acute Coronary Syndrome Exhibit Insufficient Previous Management of Cardiovascular Risk Factors: A Prospective, Observational, Single-Center Study","authors":"C. Siafarikas, S. Liatis, C. Kapelios, M. Skouloudi, M. Bonou, J. Barbetseas","doi":"10.31487/j.jicoa.2022.03.02","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.03.02","url":null,"abstract":"Objectives: Optimal regulation of modifiable risk factors, has been proposed as the standard of care, both for primary and secondary prevention of cardiovascular disease (CVD). The aim of this study was to investigate at what extent individuals who experienced an acute coronary syndrome (ACS) had previously been receiving adequate preventive measures against classical risk factors for CVD. \u0000Methods: Data were analysed for all 185 hospitalized patients with a diagnosis of ACS in the Cardiology department of our hospital during an annual period (1/7/2019 until 30/6/2020). The study population was divided into two groups, primary and secondary prevention subgroups, according to the previous medical history of CAD.\u0000Results: The mean age of the participants was 65.5 ±12.2 years and most patients were male (81.6%). Fifty-seven patients (30.8%) had a history of diabetes mellitus (DM) and 97 (52.4%) had a history of dyslipidemia. Hypertension was present in 101 (54.6%) patients and coronary artery disease (CAD) in 51 (27.9%). In the secondary prevention group, the LDL-C was on target in only one-third, while one out of 5 patients did not use statins. The use of antiplatelet/anticoagulant agents was 94.5%. Among patients with diabetes, only one out of five patients had been using a GLP-1 receptor agonist or/and an SGLT-2 inhibitor, while the HbA1c was on target in half of them. One-quarter of the patients were active smokers. In the primary prevention group, the use of statins was overall low (25.8%) but more frequent in patients with diabetes and those without diabetes at very high-risk (47.1% and 32.1%, respectively). Overall, the LDL-C was on target in less than one-quarter of patients. The use of antiplatelet/anticoagulant agents was low (20.1%), but higher in those with diabetes (52.9%). In the diabetic group, HbA1c was on target at 61.8%. Active smoking was practiced by more than one-third of the patients.\u0000Conclusion: Our data show that in a substantial proportion of patients presenting with ACS, previous CVD prevention, both primary and secondary, fails to meet the current recommendations provided by scientific societies.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42190210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-30DOI: 10.31487/j.jicoa.2022.02.02
Vasilopoulou Angeliki, Georgas A, Hristoforou E
Nowadays, problems in healthcare sector seem to be more crucial than ever. Among these, cardiovascular diseases (CVDs) play an important role, being for years a major threat to human health. In a bid to reduce the number of deaths due to heart diseases by taking precautions, science has turned to the development of devices able to offer early diagnosis of a heart failure. Recently, many biosensors have been developed based on cardiac biomarkers that can be detected in blood and predict the risk of heart failure. Of these, cardiac troponin is the best known, while C-reactive protein and myoglobin have also been used. Troponin is a complex of proteins found in the thin filaments of striated muscles and consists of three protein subunits, I, C and T. In case of myocardial malfunction, troponin is released into the blood. Consequently, the detection of elevated troponin levels at an early stage in human serum, is an indication of high risk of cardiovascular event enabling early medical intervention and treatment. In the present work, after the analysis of heart diseases, medical tests, troponin and its role in controlling myocardial health, there is an overview of the available biosensor platforms for cardiac biomarkers detection.
{"title":"A Review on Cardiac Biomarkers Detection for Heart Failure Prognosis","authors":"Vasilopoulou Angeliki, Georgas A, Hristoforou E","doi":"10.31487/j.jicoa.2022.02.02","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.02.02","url":null,"abstract":"Nowadays, problems in healthcare sector seem to be more crucial than ever. Among these, cardiovascular diseases (CVDs) play an important role, being for years a major threat to human health. In a bid to reduce the number of deaths due to heart diseases by taking precautions, science has turned to the development of devices able to offer early diagnosis of a heart failure. Recently, many biosensors have been developed based on cardiac biomarkers that can be detected in blood and predict the risk of heart failure. Of these, cardiac troponin is the best known, while C-reactive protein and myoglobin have also been used. Troponin is a complex of proteins found in the thin filaments of striated muscles and consists of three protein subunits, I, C and T. In case of myocardial malfunction, troponin is released into the blood. Consequently, the detection of elevated troponin levels at an early stage in human serum, is an indication of high risk of cardiovascular event enabling early medical intervention and treatment. In the present work, after the analysis of heart diseases, medical tests, troponin and its role in controlling myocardial health, there is an overview of the available biosensor platforms for cardiac biomarkers detection.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46499327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-18DOI: 10.31487/j.jicoa.2022.02.03
C. Coimbra, Daniel Carvalho de Lima, H. Campos, Lucas Rios Drummond, Simonton Andrade Silveira, Andrea Siqueira Haibara
The present study shows that hyperglycemic response to hemorrhage is an easy method for evaluating metabolic adjustments in normal rats and in other models that show autonomic and metabolic imbalances. In this regard, the baroreflex control of hyperglycemic response induced by hemorrhage hypotension was evaluated by removing blood through the jugular catheter (1.2 mL/100g b.w./ 2 min). Blood samples (0.2mL) were collected immediately before hemorrhage and at 5, 10, 20 and 30 minutes after hemorrhage [1, 2]. In addition, the baroreflex control of heart rate was assessed by pharmacological test, using intravenous doses of phenylephrine hydrochloride (PE, 10 μg/mL) and sodium nitroprusside (SNP, 10 μg/mL) in random order. Heart rate and blood pressure were measured through the insertion of a polyethylene catheter inserted into the abdominal aorta through the left femoral artery. The derived variables of baroreflex control to heart rate and hemorrhage hyperglycemia response were measured according to the following equation: Y = A1/{1+ exp[A2(X - A3)]} + A4. The evaluation of a new approach for studying the baroreflex effects on metabolic adjustments was done with animals fed with a hypercaloric diet. Hypercaloric diet induced an upward shift in the baroreflex curve to heart rate (p<0.05) and an increased heart rate reflex due to the change in MAP during the operating range (p<0.05). It also shifted the baroreflex curve to a higher level of hyperglycemic response to hemorrhage (p<0.05), as well as, increased maximal gain (p<0.05) and augmented hyperglycemic response to hemorrhage hypotension during the operating range (p<0.05). Therefore, we propose that the baroreflex control of hyperglycemic response should be a useful tool for evaluating metabolic dysfunction related to hemorrhage in models of animals that show autonomic imbalance, such as malnutrition, hypertension, diabetes and obesity.
{"title":"Hemorrhage Hypotension Influences on Plasma Glucose Concentration: A New Approach for Evaluating Baroreflex Effects on Metabolic Adjustments","authors":"C. Coimbra, Daniel Carvalho de Lima, H. Campos, Lucas Rios Drummond, Simonton Andrade Silveira, Andrea Siqueira Haibara","doi":"10.31487/j.jicoa.2022.02.03","DOIUrl":"https://doi.org/10.31487/j.jicoa.2022.02.03","url":null,"abstract":"The present study shows that hyperglycemic response to hemorrhage is an easy method for evaluating metabolic adjustments in normal rats and in other models that show autonomic and metabolic imbalances. In this regard, the baroreflex control of hyperglycemic response induced by hemorrhage hypotension was evaluated by removing blood through the jugular catheter (1.2 mL/100g b.w./ 2 min). Blood samples (0.2mL) were collected immediately before hemorrhage and at 5, 10, 20 and 30 minutes after hemorrhage [1, 2]. In addition, the baroreflex control of heart rate was assessed by pharmacological test, using intravenous doses of phenylephrine hydrochloride (PE, 10 μg/mL) and sodium nitroprusside (SNP, 10 μg/mL) in random order. Heart rate and blood pressure were measured through the insertion of a polyethylene catheter inserted into the abdominal aorta through the left femoral artery. The derived variables of baroreflex control to heart rate and hemorrhage hyperglycemia response were measured according to the following equation: Y = A1/{1+ exp[A2(X - A3)]} + A4. The evaluation of a new approach for studying the baroreflex effects on metabolic adjustments was done with animals fed with a hypercaloric diet. Hypercaloric diet induced an upward shift in the baroreflex curve to heart rate (p<0.05) and an increased heart rate reflex due to the change in MAP during the operating range (p<0.05). It also shifted the baroreflex curve to a higher level of hyperglycemic response to hemorrhage (p<0.05), as well as, increased maximal gain (p<0.05) and augmented hyperglycemic response to hemorrhage hypotension during the operating range (p<0.05). Therefore, we propose that the baroreflex control of hyperglycemic response should be a useful tool for evaluating metabolic dysfunction related to hemorrhage in models of animals that show autonomic imbalance, such as malnutrition, hypertension, diabetes and obesity.","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48889620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：